Literature DB >> 15801827

Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.

Bart L Staker1, Michael D Feese, Mark Cushman, Yves Pommier, David Zembower, Lance Stewart, Alex B Burgin.   

Abstract

Human topoisomerase I (top1) is the molecular target of a diverse set of anticancer compounds, including the camptothecins, indolocarbazoles, and indenoisoquinolines. These compounds bind to a transient top1-DNA covalent complex and inhibit the resealing of a single-strand nick that the enzyme creates to relieve superhelical tension in duplex DNA. (Hertzberg, R. P.; et al. Biochem. 1989, 28, 4629-4638. Hsiang, Y. H.; et al. J. Biol. Chem 1985, 260, 14873-14878. Champoux, J. J. Annu. Rev. Biochem. 2001, 70, 369-413. Stewart, L.; et al. Science 1998, 729, 1534-1541.) We report the X-ray crystal structures of the human top1-DNA complex bound with camptothecin and representative members of the indenoisoquinoline and indolocarbazole classes of top1 poisons. The planar nature of all three structurally diverse classes allows them to intercalate between DNA base pairs at the site of single-strand cleavage. All three classes of compounds have a free electron pair near Arg364, a residue that if mutated confers resistance to all three classes of drugs. The common intercalative binding mode is augmented by unexpected chemotype-specific contacts with amino acid residues Asn352 and Glu356, which adopt alternative side-chain conformations to accommodate the bound compounds. These new X-ray structures explain how very different molecules can stabilize top1-DNA covalent complexes and will aid the rational design of completely novel structural classes of anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801827     DOI: 10.1021/jm049146p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  105 in total

1.  Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Authors:  Dhriti Sooryakumar; Thomas S Dexheimer; Beverly A Teicher; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2011-06-02       Impact factor: 6.261

2.  Targeted metagenomics: finding rare tryptophan dimer natural products in the environment.

Authors:  Fang-Yuan Chang; Melinda A Ternei; Paula Y Calle; Sean F Brady
Journal:  J Am Chem Soc       Date:  2015-05-04       Impact factor: 15.419

Review 3.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

4.  Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines.

Authors:  Venita Gresham Watson; Nicholas E Hardison; Tyndall Harris; Alison Motsinger-Reif; Howard L McLeod
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

5.  Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-23       Impact factor: 7.446

6.  Crystallographic trapping in the rebeccamycin biosynthetic enzyme RebC.

Authors:  Katherine S Ryan; Annaleise R Howard-Jones; Michael J Hamill; Sean J Elliott; Christopher T Walsh; Catherine L Drennan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-14       Impact factor: 11.205

7.  Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

Authors:  Maris A Cinelli; Andrew Morrell; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

8.  Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2006-10-28       Impact factor: 1.810

Review 9.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

10.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.